Table 1.
Quantitative evaluation of the combination treatment with PQ912 and m6-Ab for 16 weeks, applying the Bliss model. The parameters are: % mean response (Ex = % decrease of Aβ in respective group x compared to isotype control) for different groups, and calculated Bliss additivity and Bliss combination index (CIBliss) for Aβ42 and pGlu-Aβ42 in soluble and insoluble brain fractions; CIBliss are given, if a robust (significant ANOVA) effect on Aβ level was observed (compare to Figure 1 and Figure 2).
| m6-Ab (ED) |
PQ912 (EE) |
Combi (EF) |
Bliss Additivity (ED + EE − ED ∗ EE) |
CIBliss (ED + EE − ED ∗ EE)/EF |
Rating of CI According to Chou [37] | |
|---|---|---|---|---|---|---|
| Aβ biochemistry | ||||||
| soluble pE-Aβ42 | 21.6 | 31.5 | 53.0 | 46.3 | 0.87 | slight synergism |
| insoluble pE-Aβ42 | 16.4 | 30.2 | 45.7 | 41.6 | 0.91 | nearly additive |
| soluble Aβ42 | 29.8 | 23.1 | 45.4 | 46.0 | 0.99 | (nearly) additive |
| Aβ Histochemistry | ||||||
| pE3Aβ (K17) | 34.6 | 41.0 | 64.5 | 61.4 | 0.95 | nearly additive |